Autoantibodies to oxidized ldl in hyperlotdemic patients treated with hmg-coa reductase inhibitors

M. N. Bui, M. T. Caulfield, P. Katz, R. O. Cannon, C. E. Rackley

Research output: Contribution to journalArticle

Abstract

Recent studies demonstrated that HMG-CoA reductase inhibitors slowed the progression and reduced the number of coronary events. Plaque stabilization has been proposed as an early beneficial mechanism. Nonisotopic ELISA technique was used to measure ox-LDL autoantibodies titers in 11 patients with hyperlipidemia LDL , IgG and IgM autoantibodies titers were measured at baseline and at 4 months after treatment with HMG-CoA reductase inhibitors. Baseline 4 months 12 months ofpauents 11 11 6 LDL(mg/dl) 173 ±37 138 ±28 128 ±15 Autoantibodies to ox-LDL<OD) IgG 0.138±0.076 0.154 + 0.087 0.180 + 0.071 IgM 0024 ±0.019 0.053± 0.044 p-valuc< 0.05 vs. baseline by paired Student t-test OD: optical density Six of the 11 patients had a 12-month follow-up with a mean IgG titer of 0.180 which was not significantly different from their baseline titer. There was no correlation between the magnitude of LDL reduction and changes in autoantibody titers. Conclusion: 1) With HMG-CoA reductase inhibitors, a decrease in LDL level was associated with an initial increase in autoantibodies titers to ox-LDL 2) Early increase in autoantibody titers was greater with IgM than IgG. 3) These early immune responses may be involved in plaque stabilization.

Original languageEnglish (US)
Pages (from-to)296a
JournalJournal of Investigative Medicine
Volume44
Issue number3
StatePublished - Jan 1 1996

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Autoantibodies to oxidized ldl in hyperlotdemic patients treated with hmg-coa reductase inhibitors'. Together they form a unique fingerprint.

  • Cite this

    Bui, M. N., Caulfield, M. T., Katz, P., Cannon, R. O., & Rackley, C. E. (1996). Autoantibodies to oxidized ldl in hyperlotdemic patients treated with hmg-coa reductase inhibitors. Journal of Investigative Medicine, 44(3), 296a.